Stock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| CYB003 (Deuterated Psilocin Oral) | Major Depressive Disorder (MDD) adjunct | Phase 3 | Dec 31, 2026 | Potential moverHedge fund avoid |
Upcoming milestones
Company profile
Cybin is a biotechnology company in the healthcare sector.
Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Major Depressive Disorder (MDD) adjunct